ClinicalTrials.gov
ClinicalTrials.gov Menu

Alternate-Day Buprenorphine Administration. Phase VI - 7

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000225
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : June 24, 2005
Sponsor:
Collaborator:
University of Vermont
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to determine if four times a subject's daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Drug: Buprenorphine Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 0 participants
Masking: Double
Primary Purpose: Treatment
Official Title: Alternate-Day Buprenorphine Administration. Phase VI
Study Start Date : December 1992

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Drug use
  2. Opioid withdrawal
  3. Opioid agonist effects
  4. Dose identification
  5. Pupil diameter


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 51 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000225


Locations
United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of Vermont
Investigators
Principal Investigator: Warren Bickel, Ph.D. University of Vermont

Publications:
patry, Bickel, Tzanis, Badger (in preparation). Every fourth day dosing with buprenorphine (1) A comparison of four schedules under blind-dosing procedures.. Patry, Bickel, Tzanis, Badger (in preparation). Every fourth day dosing with buprenorphine (1) A comparison of four different dosing schedules under blind-dosing procedures.

ClinicalTrials.gov Identifier: NCT00000225     History of Changes
Other Study ID Numbers: NIDA-06969-7
R01-06969-7
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: June 2004

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists